🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

210 results for “Ovid” Clear

  1. mavrilimumab

    Kiniksa Pharmaceuticals International, plc

    COVID

    phase 3 small molecule completed

    1 trial

  2. sotrovimab

    Vir Biotechnology

    Covid19

    phase 3 mab terminated

    3 trials

  3. vitamin D

    Takeda Pharmaceuticals International AG

    COVID-19

    phase 3 other completed

    1 trial

  4. ACT-20-MSC

    Aspire Biopharma Holdings

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  5. ADX-629

    Aldeyra Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial

  6. APL-9

    Apellis Europe B.V.

    COVID

    phase 2 small molecule completed

    1 trial

  7. ARCT-021 single dose priming

    Arcturus Therapeutics Holdings

    Covid19

    phase 2 mab terminated

    1 trial

  8. ARCT-165

    Arcturus Therapeutics Holdings

    COVID-19

    phase 2 mab completed

    1 trial

  9. AT-527

    Atea Pharmaceuticals

    COVID-19

    phase 2 small molecule terminated

    2 trials

  10. Alvelestat

    Mereo BioPharma Group plc

    Covid19

    phase 2 small molecule completed

    1 trial

  11. Analogs, Prostaglandin E1

    Vera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  12. Aprepitant injectable emulsion

    Heron Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  13. BEVACIZUMAB

    Pari Pharma GmbH

    Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.

    phase 2 small molecule active

    1 trial

  14. Bamlanivimab

    Vir Biotechnology

    COVID-19

    phase 2 small molecule completed

    1 trial

  15. CAP-1002

    CAPRICOR THERAPEUTICS, INC.

    Covid19

    phase 2 mab completed

    1 trial

  16. CERC-002

    Avalo Therapeutics

    COVID-19 Pneumonia

    phase 2 small molecule completed

    1 trial

  17. COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)

    SINOVAC BIOTECH LTD

    COVID-19

    phase 2 mab terminated

    1 trial

  18. COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

    SINOVAC BIOTECH LTD

    COVID-19

    phase 2 mab completed

    1 trial

  19. CYSTAGON 150 mg hard capsules

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Infectious diseases of respiratory system (COVID-19)

    phase 2 small molecule active

    1 trial

  20. Comirnaty JN.1 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, LVT-001

    Tour Hekla

    Healthy volunteers

    phase 2 small molecule active

    1 trial

  21. Convalescent Plasma

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 mab terminated

    1 trial

  22. CoronaVac®

    SINOVAC BIOTECH LTD

    COVID-19

    phase 2 mab completed

    1 trial

  23. Defibrotide

    Jazz Pharmaceuticals Ireland Limited

    Covid19

    phase 2 small molecule active

    1 trial

  24. Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Dexamethason 4 mg JENAPHARM®, teclistamab, teclistamab, Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 2 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Pomalidomide, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Im

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources